Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
January 26, 2024 16:05 ET
|
Autonomix Medical, Inc.
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
SeaStar Medical Appoints David A. Green as Chief Financial Officer
January 11, 2024 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Autonomix Medical, Inc. to Present at the Startup Investing Webinar
January 11, 2024 09:00 ET
|
Autonomix Medical, Inc.
Live webcast roundtable discussion featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11th at 2:00 PM ET THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
January 09, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones
January 04, 2024 10:00 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Patented two-fold technology that can potentially detect problematic neural signals and ablate nerves in one simple...
GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
January 02, 2024 12:33 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
November 30, 2023 17:39 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...
Autonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors
November 16, 2023 10:00 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how...
QHSLab, Inc. (USAQ) Reports Third Quarter Financial Results
November 14, 2023 08:30 ET
|
QHSLab, Inc.
25% Y-O-Y Revenue Growth in Q3 2023 Compared to Q3 2022 and 51% Increase in Gross Profit. ●In Q3 2023, QHSLab generated $336,407 in revenues, reflecting a notable 25% year-over-year increase from...
GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE
November 13, 2023 09:00 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...